23-01-2020
servickuz / shutterstock.com
A competitor of the Broad Institute has said that a European Patent Office (EPO) ruling last week has weakened the CRISPR/Cas9 patent owner’s negotiating hand in any future settlement between the parties.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
ERS Genomics, Broad Institute, CRISPR/Cas9, Eric Rhodes, Emmannuelle Charpentier, settlement
USPTO rules Broad owns CRISPR animal cell editing patents
01-03-2022
Zebrafish start-up secures CRISPR licence
18-02-2021
EPO reveals decision behind Broad patent revocation
09-11-2020
ERS Genomics appoints vice-president of IP
23-09-2020
Broad and ERS Genomics both claim victory in latest CRISPR ruling
14-09-2020
